"
Team:Westminster/Project/Overview
From 2012.igem.org
(Difference between revisions)
| Line 120: | Line 120: | ||
margin: 10px 0px 50px 20px; | margin: 10px 0px 50px 20px; | ||
border-radius: 10px; | border-radius: 10px; | ||
| + | } | ||
| + | div.centered { | ||
| + | position: relative; | ||
| + | width: 400px; | ||
| + | margin: 10px auto; | ||
} | } | ||
div#footer-box { | div#footer-box { | ||
| Line 155: | Line 160: | ||
<li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li> | <li><a href="https://igem.org/Team.cgi?year=2012&team_name=Westminster"class="navlink">Team Profile</a></li> | ||
<li class="submenu-holder"> | <li class="submenu-holder"> | ||
| - | <a href="https://2012.igem.org/Team:Westminster/Project/Overview"class="navlink | + | <a href="https://2012.igem.org/Team:Westminster/Project/Overview"class="navlink">Project</a> |
<ul class="submenu"> | <ul class="submenu"> | ||
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink active">Overview</a></li> | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Overview"class="navlink active">Overview</a></li> | ||
| Line 164: | Line 169: | ||
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | ||
<li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li> | <li class="submenu-button"><a href="https://2012.igem.org/Team:Westminster/Journal"class="navlink">Journal</a></li> | ||
| - | + | </ul> | |
| - | <li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink">Modeling</a></li> | + | </li> |
| + | <li><a href="https://2012.igem.org/Team:Westminster/Parts"class="navlink">Parts</a></li> | ||
| + | <li><a href="https://2012.igem.org/Team:Westminster/Modeling"class="navlink active">Modeling</a></li> | ||
<li><a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Notebook"class="navlink">Notebook</a></li> | ||
<li><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | <li><a href="https://2012.igem.org/Team:Westminster/Safety"class="navlink">Safety</a></li> | ||
| Line 179: | Line 186: | ||
<div id="home-main-text"> | <div id="home-main-text"> | ||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
| - | |||
<h2>Lorem Ipsum</h2> | <h2>Lorem Ipsum</h2> | ||
<p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p> | <p>Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.</p> | ||
Latest revision as of 17:53, 26 September 2012
Lorem Ipsum
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
Lorem Ipsum
Cancer recurrence is one of the fears that almost every patient undergoing chemotherapy develops. Recent findings suggest that only a small fraction of the tumor cells, called Cancer Stem Cells (CSC) are able to drive the growth of the tumor. CSC also show an increased drug resistance, and could remain unaffected after chemotherapy, eventually resulting in the formation of a new tumor.
